Breast Cancer Clinical Trial
Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Summary
This study compares molecular breast imaging (MBI) and digital breast tomosynthesis (DBT) in screening patients with dense breast tissue. Breast imaging may help doctors find breast cancer sooner, when it may be easier to treat. Molecular breast imaging (MBI) uses an injection of a small amount of radioactive material that is taken up in tissues of the body that are actively changing, such as breast cancer. A specialized camera, called a gamma camera, takes pictures of the gamma rays emitted by this material. MBI may detect cancers that are not visible on mammograms. This study may help researchers determine how MBI testing compares to DBT screening.
Full Description
PRIMARY OBJECTIVE:
I. To compare the rate of detection of invasive cancers between digital breast tomosynthesis (DBT) alone versus (vs.) the combination of DBT with supplemental MBI at year 0 screening.
SECONDARY OBJECTIVES:
I. To compare the invasive cancer detection rates of DBT alone vs. MBI alone at year 0 screening.
II. To compare the screening performance metrics of sensitivity, specificity, recall rate, biopsy rate, positive predictive value and negative predictive value for DBT and MBI.
III. To compare tumor characteristics of all cancers (invasive and noninvasive) detected on DBT and MBI, including size, nodal status, and molecular subtype.
IV. To assess the reduction in advanced cancer rate with incorporation of MBI screening by comparing advanced cancer rate observed at year 1 screening relative to that at year 0.
V. To assess the rate of interval cancers with incorporation of MBI screening. VI. To examine the relative performance of DBT and MBI within subgroups categorized by breast cancer risk.
OUTLINE:
Participants undergo DBT and MBI at year 0 and year 1 screening.
Eligibility Criteria
Inclusion Criteria:
Patient is a consenting female age 40-75 years
Patient is scheduled for routine screening DBT
Patient is asymptomatic for breast disease
Patient had heterogeneously dense or extremely dense breasts on most recent prior mammography examination (Breast Imaging Reporting and Data System [BI-RADS] c or d) within 24 months of enrollment
Patient is able to participate fully in all aspects of the study (completing study visits and study data collection)
Patient understands and signs the study informed consent
Patient anticipates being able to return one year after study enrollment to complete the second round of screening
Exclusion Criteria:
Patient is currently pregnant or plans to become pregnant during the course of the study
Patient is currently lactating
Patient has had a prior MBI
Patient has had a prior whole breast ultrasound (WBUS) for screening, with either a hand-held ultrasound probe or automated system, within 12 months prior to study enrollment
Patient has had a prior breast MRI
Patient has had a prior contrast-enhanced mammogram (contrast enhanced spectral mammography [CESM] or contrast-enhanced digital mammography [CEDM])
Patient is concurrently participating in any other breast imaging research studies that involve undergoing additional breast imaging tests beyond routine screening with mammography, including but not limited to contrast-enhanced mammography, WBUS, MBI, or contrast-enhanced breast MRI
Patient has had a breast biopsy within 3 months prior to study enrollment
Patient has had breast surgery within 12 months prior to study enrollment
Patient is currently undergoing treatment for breast cancer or planning surgery for a high-risk breast lesion (atypical ductal hyperplasia [ADH], atypical lobular hyperplasia [ALH], lobular carcinoma in situ [LCIS], papilloma, radial scar)
Patient is currently taking a chemoprevention agent for breast cancer risk reduction or osteoporosis prevention (tamoxifen, raloxifene, anastrazole, letrozole, exemestane)
Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Detroit Michigan, 48202, United States
Rochester Minnesota, 55905, United States More Info
Principal Investigator
Toledo Ohio, 43623, United States
Houston Texas, 77030, United States More Info
Principal Investigator
La Crosse Wisconsin, 54601, United States
How clear is this clinincal trial information?